Results 251 to 260 of about 3,443,356 (396)

Enhancing PARP inhibitor efficacy in ovarian cancer: targeting the PI3K/AKT/mTOR pathway. [PDF]

J Ovarian Res
Wang Y, Xia Q, Wang X, Lu Y, Wang S, Jiao Y.   +5 more
europepmc   +1 more source

The CDK1 inhibitor RO3306 improves the response of BRCA-proficient breast cancer cells to PARP inhibition

, 2013
Qing Xia, Yuchen Cai, Roujun Peng, Guosheng Wu, Yanxia Shi, Wenqi Jiang   +5 more
openalex   +2 more sources

Liquid biopsy in genitourinary oncology: Current clinical applications and future prospects across prostate, bladder, and renal cancers

UroPrecision, EarlyView.
Abstract Liquid biopsy has emerged as a transformative approach in oncology, providing minimally invasive access to tumor‐derived biomarkers with applications across diagnosis, prognosis, therapeutic guidance, and disease monitoring. This literature review synthesizes evidence from 125 studies evaluating circulating tumor DNA, circulating tumor cells ...
Kirolos Eskandar
wiley   +1 more source

Tumor cell-derived IFN spatially reprograms osteopontin-enriched macrophage niches to promote PARP inhibitor resistance. [PDF]

J Clin Invest
Liu D, Tao K, Xu C, Yang W, Cai C, Feng C, Xiong K, Wu S, Lin Y, Peng Z, Chi J, Pan W, Zhong Q, Liu J, Li X, Liu X, Zhou D, Ma D, Zhao GN, Xia Y, Fang Y, Gao Q.   +21 more
europepmc   +1 more source

Staging concept for aging management: Definition, mechanism, and coping strategies

VIEW, EarlyView.
We divided the overall aging stage into “pre‐aging”, “aging compensation”, and “aging disability”. For each stage, we delineate the clinical presentations, biological phenomena, theoretical underpinnings, and key management priorities. Abstract Aging, as a gradual and largely irreversible biological process, characterized by declining organismal ...
Zhonghan Wang, Shixian Liu, Shangyu Du, Xiangran Cui, Bo Chao, Minglei Liu, Minfei Wu   +6 more
wiley   +1 more source

Exploring the optimal cutoff point and genomic characteristics for PARP inhibitor maintenance therapy in early recurrence of ovarian cancer. [PDF]

J Ovarian Res
Ye L, Chen Y, Chen Y, Zhao Q, Cheng X, Wang X, Xu X, Guo W, Chen X, Ni J.   +9 more
europepmc   +1 more source

Cryo‐EM structure of ALC1 in an open conformation bound to a PARylated nucleosome

Acta Crystallographica Section D, EarlyView.
Reanalysis of a publicly available cryo‐EM dataset identifies a new conformation of the oncogenic chromatin remodeler ALC1/CHD1L bound to a PARylated nucleosome. This new structure reveals the position of the macro domain in the complex, and may help to understand the large conformational change leading to the activation of ALC1.Nucleosomes are the ...
Hannah R. Bridges, Luka Bacic, Sebastian Deindl, Guillaume Gaullier   +3 more
wiley   +1 more source

Impairment of oxidative metabolism compromises Rad51 recruitment and potentiates PARP inhibitor effectiveness in ovarian cancer. [PDF]

J Exp Clin Cancer Res
Formenti L, Abramo F, Dellavedova G, Dematteis V, Decio A, Grasselli C, Fabbrizio P, Brunelli L, Giavazzi R, Ghilardi C.   +9 more
europepmc   +1 more source

Management of Advanced Prostate Cancer in the Asia‐Pacific Region: Summary of the Asia‐Pacific Advanced Prostate Cancer Symposium 2025

Asia-Pacific Journal of Clinical Oncology, EarlyView.
Summary of the Asia Pacific Advanced Prostate Cancer Symposium 2025, showing disciplines and diversity of participants, discussion topics (high‐risk localized/locally advanced prostate cancer; PSA persistence and recurrence; radioligand therapy; genetics and genomics; bone protection and other aspects of supportive care), key themes, and high‐level ...
Edmund Chiong, Renu Eapen, Nicholas Buchan, Kenneth Chen, Lukman Hakim, Agus Rizal Hamid, Jae‐Young Joung, Ravindran Kanesvaran, Makarand Khochikar, Jason Letran, Bannakij Lojanapiwat, Indranil Mallick, Chi Fai Ng, Pei Ing Ngam, Teng Aik Ong, Jacob Pang, Darren M. C. Poon, Natasha Roberts, Marniza Saad, Shinichi Sakamoto, Jeremy Tey, Sue Ping Thang, Poh Choo Toh, Levent Türkeri, Nguyễn Tuấn Vinh, Alvin Wong, Yao Zhu, ANZUP Cancer Trials Group, Ian D. Davis   +28 more
wiley   +1 more source

Novel therapeutic potential of the PARP inhibitor talazoparib in synovial sarcoma and its combined effect with ATR inhibitor. [PDF]

Discov Oncol
Honda N, Taniguchi H, Ono S, Hayashi F, Imamura E, Gyotoku H, Takemoto S, Takazono T, Ishimoto H, Sakamoto N, Obase Y, Masutani M, Nishino T, Mukae H.   +13 more
europepmc   +1 more source